Emily J. Lelliott

756 total citations
10 papers, 337 citations indexed

About

Emily J. Lelliott is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Emily J. Lelliott has authored 10 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Molecular Biology and 4 papers in Immunology. Recurrent topics in Emily J. Lelliott's work include Cancer Immunotherapy and Biomarkers (4 papers), Melanoma and MAPK Pathways (4 papers) and CAR-T cell therapy research (3 papers). Emily J. Lelliott is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Melanoma and MAPK Pathways (4 papers) and CAR-T cell therapy research (3 papers). Emily J. Lelliott collaborates with scholars based in Australia and United States. Emily J. Lelliott's co-authors include Grant A. McArthur, Karen E. Sheppard, Jane Oliaro, Kelly M. Ramsbottom, Conor J. Kearney, Ricky W. Johnstone, Stephin J. Vervoort, Jessica Michie, Lorey Smith and Phillip K. Darcy and has published in prestigious journals such as Scientific Reports, Science Advances and Cell Death and Differentiation.

In The Last Decade

Emily J. Lelliott

10 papers receiving 336 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emily J. Lelliott Australia	9	195	181	107	43	29	10	337
L. Orgiano Italy	8	226 1.2×	180 1.0×	108 1.0×	34 0.8×	20 0.7×	13	382
Ashleigh Stewart Australia	6	278 1.4×	209 1.2×	206 1.9×	34 0.8×	19 0.7×	15	425
Michelle S. Miller United States	12	149 0.8×	284 1.6×	78 0.7×	49 1.1×	24 0.8×	27	517
Kelsey W. Nassar United States	5	170 0.9×	164 0.9×	84 0.8×	36 0.8×	10 0.3×	6	284
Irene Manrique Spain	9	199 1.0×	206 1.1×	58 0.5×	28 0.7×	14 0.5×	15	384
Ludimila Cavalcante United States	12	238 1.2×	148 0.8×	82 0.8×	78 1.8×	16 0.6×	54	423
Angela Sandru Romania	8	159 0.8×	155 0.9×	53 0.5×	38 0.9×	18 0.6×	11	299
Pauline L. de Goeje Netherlands	6	196 1.0×	136 0.8×	155 1.4×	61 1.4×	13 0.4×	6	375
Janice M. Mehnert United States	8	183 0.9×	303 1.7×	52 0.5×	36 0.8×	12 0.4×	24	409

Countries citing papers authored by Emily J. Lelliott

Since Specialization

Citations

This map shows the geographic impact of Emily J. Lelliott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily J. Lelliott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily J. Lelliott more than expected).

Fields of papers citing papers by Emily J. Lelliott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily J. Lelliott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily J. Lelliott. The network helps show where Emily J. Lelliott may publish in the future.

Co-authorship network of co-authors of Emily J. Lelliott

This figure shows the co-authorship network connecting the top 25 collaborators of Emily J. Lelliott. A scholar is included among the top collaborators of Emily J. Lelliott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily J. Lelliott. Emily J. Lelliott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Lelliott, Emily J., Katherine Ganio, Jessica Michie, et al.. (2024). Intracellular zinc protects tumours from T cell-mediated cytotoxicity. Cell Death and Differentiation. 31(12). 1707–1716. 3 indexed citations

Lelliott, Emily J., Karen E. Sheppard, & Grant A. McArthur. (2022). Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?. npj Precision Oncology. 6(1). 26–26. 22 indexed citations

Lelliott, Emily J., Kelly M. Ramsbottom, Mark R. Dowling, et al.. (2022). NKG7 Enhances CD8+ T Cell Synapse Efficiency to Limit Inflammation. Frontiers in Immunology. 13. 931630–931630. 18 indexed citations

Kearney, Conor J., Stephin J. Vervoort, Kelly M. Ramsbottom, et al.. (2021). SUGAR-seq enables simultaneous detection of glycans, epitopes, and the transcriptome in single cells. Science Advances. 7(8). 60 indexed citations

Lelliott, Emily J., Grant A. McArthur, Jane Oliaro, & Karen E. Sheppard. (2021). Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. Frontiers in Immunology. 12. 661737–661737. 39 indexed citations

Lelliott, Emily J., Stefano Mangiola, Kelly M. Ramsbottom, et al.. (2020). Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma. Cancer Immunology Research. 9(2). 136–146. 15 indexed citations

Smith, Lorey, et al.. (2020). Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?. Cancers. 12(6). 1583–1583. 32 indexed citations

Michie, Jessica, Paul A. Beavis, Andrew J. Freeman, et al.. (2019). Antagonism of IAPs Enhances CAR T-cell Efficacy. Cancer Immunology Research. 7(2). 183–192. 77 indexed citations

Lelliott, Emily J., Carleen Cullinane, Claire Martin, et al.. (2019). A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy. Scientific Reports. 9(1). 1225–1225. 17 indexed citations

10.

Martin, Claire, Carleen Cullinane, Laura Kirby, et al.. (2017). Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance. International Journal of Cancer. 142(10). 2139–2152. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact